REDMILE β Full Portfolio
17 tracked investments Β· listed companies and verified rows first
Absci uses an AI-based drug creation platform combined with wet lab validation to design biologic therapeutics such as antibodies from scratch.
AI & Machine LearningBiotechDeep TechPortland, US
Sean McClain(Executive Officer)inPhil Barish(Executive Officer)
BoardZach Jonasson(Director)Daniel Gold(Director)Bryan Lawlis(Director)
Co-investorsDas & Co.Oregon Venture FundPhoenix Venture PartnersTachyon VenturesTau VenturesBiotechnology Value Fund+2 more
Abcuro develops therapies that target highly cytotoxic T cells for autoimmune diseases, including its lead candidate ulviprubart for inclusion body myositis.
BiotechHealthtechNewton, US
Steven A. Greenberg(Chief Scientific Advisor & Co-Founder)Steven A. Greenberg, MD(Chief Scientific Advisor & Co-Founder)John Alexander Martin(Executive Officer, Director)Stefano Gulla(Executive Officer)Evan Thompson(Executive Officer)David de Graaf(Executive Officer, Director)
Co-investorsBain Capital Life SciencesNew Enterprise Associates (NEA)RA CapitalSamsara BioCapitalSanofi VenturesMass General Brigham Ventures+8 more
Bambusa Therapeutics develops bispecific antibodies for immunological and inflammatory (I&I) disorders, using antibody engineering to target multiple I&I indications.
BiotechHealthtechMedical DevicesAustin, US
Shanshan Xu(Founder & Chief Executive Officer)inHelmut Jeggle(Co-Founder)inThang Ho(Chief Development Officer)Crystal MacKay(Chief Operating Officer)in
Co-investorsINCE CapitalRA CapitalBiotechnology Value FundJanus Henderson InvestorsSalvia
GRObio (GRO Biosciences) develops protein therapeutics using non-standard amino acids (NSAAs) via its GRO platform, aiming to improve protein potency, stability, and function.
BiotechDeep TechHealthtechCambridge, US
Daniel J Mandell(Executive Officer, Director)Tracey Lodie(Executive Officer)Christopher Gregg(Director)
BoardMing Fang(Director)Bruce Beutel(Director)Dan Becker(Director)
Co-investorsLeaps by BayerDigitalis VenturesDreamers VCRising TideAtlas VentureInnovation Endeavors+1 more
Home Biosciences was a venture builder in Continental Europe dedicated to creating and scaling biotech companies through an asset-centric, hub-and-spoke model, working with academics and scientists on drug discovery and molecular profiling projects.
AI & Machine LearningBiotechHealthtech
David Schilansky(Co-founder & Non-executive Chairman)inMagali Richard(Co-founder)in
Co-investorsSofinnova Partners
Lycia Therapeutics is a biotechnology company developing LYTAC (Lysosomal Targeting Chimera) therapeutics that bind disease-causing extracellular and cell-surface proteins and route them into the cell's lysosome for degradation.
BiotechHealthtechSouth San Francisco, US
Aetna Wun Trombley(President and CEO)Amy Bachrodt(Chief Financial Officer)Chin Lee(Chief Medical Officer)Steve Staben(Chief Scientific Officer)Sofia Touami(Chief Business Officer)Karen Flick(General Counsel)
Co-investorsVersant VenturesBAM ElevateFranklin TempletonHBM Healthcare InvestmentsInvusJanus Henderson Investors+4 more
Ambrosia Bio produces rare sugars such as Allulose as low- to no-calorie replacements for sugar, offering a similar taste, sweetness, and textural profile without artificial aftertaste.
BiotechFoodTech
Co-investorsAnimoca BrandsBrinc
Clear Labs develops fully automated next-generation sequencing (NGS) platforms that process genomic data into insights for research and surveillance applications across infectious disease, food safety, and oncology.
BiotechData & InfrastructureDeep TechHealthtechMedical DevicesSan Carlos, US
Sasan Amini(Co-founder & CEO)Ramin Khaksar(Executive Officer)inEdward Fan(Executive Officer)inBrodie Flanders(Executive Officer, Director)Kazutaka Ohno(Executive Officer)Farzad Naimi(Executive Officer, Director)
Co-investorsMenlo VenturesKhosla VenturesNimble VenturesDentsu VenturesFelicis VenturesNimble Partners+5 more
Climb is a French wealth management service that combines advisors with technology to grow clients' assets through an open-architecture selection of investment products (life insurance, retirement PER, real estate, private equity, tax-reduction schemes, crypto).
FintechSaaS
Aldric EmiΓ©(CEO)
Co-investorsKima VenturesAlly Bridge GroupRA Capital
DealForma is a curated biopharma deals database offering licensing deal comps, M&A data, company and drug pipeline profiles, funding rounds, and Tableau-based interactive dashboards with natural-language search.
BiotechData & InfrastructureHealthtech
Co-investorsTinySeedAlgerRA CapitalRTW Investments L.P.Sofinnova Ventures
Evox Therapeutics develops exosome-based gene editing therapies using its ExoEdit platform, which combines exosome delivery with a proprietary CRISPR-based editor to treat severe neurodegenerative and other genetically-driven diseases.
BiotechDeep Tech
Co-investorsOrbiMedOxford Science EnterprisesPanacea VentureCowen Healthcare InvestmentsGV (Google Ventures)
Genalyte is developing Merlin, an automated diagnostic device that processes blood samples on-site and returns lab results within minutes while the patient waits.
Digital HealthHardwareMedical Devices
Co-investorsBioBritBoutique Venture PartnersClaremont Creek VenturesFusionX VenturesIPD CapitalSamsara BioCapital+3 more
BiotechEmeryville, US
Andrew Allen(Executive Officer, Director)Vassiliki Economides(Executive Officer)Matthew Hawryluk(Executive Officer)Shefali Agarwal(Director)Elaine Jones(Director)Naiyer A. Rizvi(Director)
Co-investorsFrazier Life SciencesSofinnova Ventures
A pharmaceutical company developing therapeutics across oncology, hematology, neuroscience, immunology, and cardiovascular disease with a pipeline of 50 compounds targeting 40+ disease areas.
BiotechHealthtechMedical Devices
Co-investorsAndreessen HorowitzARCH Venture PartnersiGlobe PartnersAgent CapitalNewpath Partners
Provides pharmaceutical R&D services via the Cyto-Mine machine for single-cell analysis and characterisation.
Co-investors24 HaymarketQVenturesProvidence Investment Company LimitedSofinnova Partners
Star Therapeutics develops treatments aimed at addressing real-world patient needs.
BiotechSouth San Francisco, US
Adam Rosenthal(Founder & CEO)Jason Hafler(Director)Nancy Stagliano(Director)Michelle Carpenter(Executive Officer)Matthew Fust(Director)Amrit Nagpal(Director)
Co-investorsFrazier Life SciencesOrbiMedRA CapitalSanofi VenturesSofinnova VenturesAgent Capital+8 more
Syros Pharmaceuticals is a Massachusetts gene-control biotech developing small molecules that regulate disease gene expression.
Co-investorsAisling CapitalARCH Venture PartnersQuan CapitalFlagship Ventures
Rows marked βSEC filingβ are inferred from directors named on the company's SEC Form D β public regulatory data, not a portfolio list published by the firm.